Los puntos clave no están disponibles para este artículo en este momento.
Advances in developing new agents for cognitive and behavioral symptoms of AD combined with enhanced trial methods promise to address the unmet needs of patients with AD for improved cognition and amelioration of neuropsychiatric symptoms.
Jeffrey L. Cummings (Wed,) studied this question.